AtaiBeckley To Host Virtual Investor Day on March 6, 2026

Core Viewpoint - AtaiBeckley Inc. is hosting a Virtual Investor Day on March 6, 2026, to present its mission and pipeline of mental health treatments [1][2]. Company Overview - AtaiBeckley Inc. is a clinical-stage biotechnology company focused on developing rapid-acting, durable, and convenient mental health treatments [3]. - The company's pipeline includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder [3]. - BPL-003 is in Phase 3 planning, while VLS-01 and EMP-01 are in Phase 2 clinical development [3]. - The company is also working on a drug discovery program for novel, non-hallucinogenic 5-HT2AR agonists targeting opioid use disorder and TRD [3]. Event Details - The Virtual Investor Day will feature presentations and live Q&A sessions with the executive leadership team and external key opinion leaders [1]. - Investors, analysts, and media members can register for the live webcast, with a replay available afterward on the company's investor website [2].